FDA Alerts Multaq Increases Risk of Death and Cardiovascular Events in Certain Users

Dec. 19, 2011 - PRLog -- The U.S. Food and Drug Administration (FDA) confirms that the heart drug, Multaq, increases the risk of serious cardiovascular events, including death, stroke and heart failure.  “According to the revised label, Multaq doubles the rate of these catastrophic events in patients with permanent atrial fibrillation,” explains David Ennis of Ennis & Ennis, P.A.  “Getting the word out quickly can save lives.”
http://www.fda.gov/Drugs/DrugSafety/ucm283933.htm

In September 2011 the European Medicines Agency, which is the European equivalent of the FDA, recommended restricted use of the anti-arrhythmic medication only to be used on a limited population of patients after all alternative treatment options had been considered.  At that time, the FDA was still conducting its own review of the safety of dronedarone, which is the active ingredient in Sanofi’s Multaq heart medication.

This isn’t the first time Multaq has faced scrutiny.  In early 2011, the FDA required Sanofi to update the Multaq label to warn of liver injury, including liver failure requiring transplant.

Multaq had world-wide sales of $179 million in the first half of 2011 and has been prescribed to more than 500,000 patients, according to The Wall Street Journal. http://online.wsj.com/article/SB1000142405297020479110457...

If you or a loved one suffered from permanent atrial fibrillation and are currently taking Multaq, consult with your physician immediately.

Ennis & Ennis P.A. is offering free nationwide confidential consultations for patients who are taking or have taken Multaq and suffered injuries by calling toll free 1-800-856-6405 or by going to www.ennislaw.com and completing an online case evaluation form.

Ennis & Ennis, P.A. is a nationwide law firm with offices in Ft. Lauderdale, Miami and Washington D.C.  Ennis & Ennis, P.A. concentrates its practice in mass torts and represents individuals against pharmaceutical companies and medical device makers.

Ennis & Ennis, P.A. has been representing clients individually since 1986 and has recovered over $100 million in settlements for its clients.

Ennis & Ennis, P.A. is also investigating cases involving Accutane, Actos, Avandia, Fosamax, Paxil, Zoloft, Prozac, Depuy Hip Recall, Wright Conserve, Wright Profemur, Zimmer Hip Recall, Depakote, Reglan, SJS/Dilantin, Yaz, Yasmin and Ocella Birth Control Pills and transvaginal mesh devices.

Remember the law limits the time in which a claim can be filed, so don’t wait to explore your legal rights.  Call today toll free 1-800-856-6405 or visit www.ennislaw.com.